Innovation in Therapeutics Nitto Avecia specializes in oligonucleotide development and manufacturing, positioning it as a leader in next-generation therapeutics with substantial expertise to support pharmaceutical companies investing in RNA-based treatments.

Strategic Collaborations Recent integration with Codexis' ECO Synthesis platform highlights opportunities for joint development of scalable, sustainable oligonucleotide manufacturing solutions appealing to organizations seeking innovative and eco-friendly therapeutic production methods.

Facility Expansion The acquisition of an additional 8.8-acre property and recent facility expansions indicate capacity growth, making Nitto Avecia a compelling partner for pharmaceutical firms looking for reliable, large-scale oligonucleotide manufacturing capacities.

Strong Market Position With annual revenues between 250 to 500 million dollars and over 30 years of industry experience, Nitto Avecia offers stability and proven expertise, which can be attractive to clients seeking dependable oligonucleotide manufacturing partners.

Technological Edge Utilizing advanced tech stacks including SAP ERP, Oracle, and Tableau, Nitto Avecia demonstrates a commitment to operational excellence and innovation, providing potential clients with confidence in quality control and scalable production solutions.